SCHEMBL15909028

SCHEMBL15909028

CC(C)(C)OC(=O)N1c2ccc(N3CCOCC3)cc2Sc2cc(N3CCOCC3)cc(C#N)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.43
▸ NR1H3 Q13133 1/20 0.43
▸ BCHE P06276 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NSD2 O96028 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ CASP6 P55212 1/20 0.39
▸ CSF1R P07333 2/20 0.38
▸ TBK1 Q9UHD2 3/20 0.38
▸ GPR119 Q8TDV5 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.37
▸ HPGD P15428 2/20 0.36
▸ IDH1 O75874 1/20 0.36
▸ XDH P47989 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13386210 0.86 BCHE (0.42) NR1H2NR1H3BCHEMAPTSMN1; SMN2
SCHEMBL13386133 0.83 BCHE (0.40) NR1H2NR1H3BCHEMAPTSMN1; SMN2
SCHEMBL13386285 0.80 BCHE (0.39) NR1H2NR1H3BCHEMAPTSMN1; SMN2
SCHEMBL13386281 0.79 PIK3CA (0.41) BCHEMAPTSMN1; SMN2LMNAGPR119
SCHEMBL13386122 0.79 BCHE (0.39) BCHESMN1; SMN2LMNATSHRGPR119
SCHEMBL15908923 0.76 BCHE (0.46) NR1H2NR1H3BCHESMN1; SMN2USP30
SCHEMBL2594780 0.74 PDK2 (0.46) BCHEMAPTSMN1; SMN2LMNATSHR
SCHEMBL2585068 0.72 SIRT6 (0.41) BCHEMAPTKDM4EHTTCSF1R
SCHEMBL21196734 0.71 BCHE (0.41) NR1H2NR1H3BCHEMAPTSMN1; SMN2
SCHEMBL9933040 0.70 BCHE (0.40) BCHEGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 — — US disclosed
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 — — US disclosed
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 — — US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 — — US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 — — US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 — — US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 — — US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 — — US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 — — US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 — — US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 — — US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease PSEN1, APP, PSEN2 NR1H2 1969/4885NR1H3 2336/4885BCHE 12/4885
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE PSEN1, APP, PSEN2 NR1H2 1969/4885NR1H3 2336/4885BCHE 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback